Medical Spa Show Exhibitor Spotlight: Oxygenetix Institute Inc

January 11, 2019

The Medical Spa Show 2019–the only national trade show directly serving medical spas and non-invasive medical aesthetic practices–will connect medical spa owners and professionals with the best service and equipment providers in the industry. 
Join AmSpa at the Aria Hotel in Las Vegas, NV, February 8–10, 2019 to meet non-invasive medical aesthetic practitioners just like you, and learn about the latest trends, techniques, and technology in the industry.
Visit www.medicalspashow.com for more information. Click here to register today!
Get to know Oxygenetix Institute Inc before you visit them at Booth 100. 

 
 
 
What is your company’s mission?Oxygenetix was formulated for post-operative healing and full, undetectable coverage, continued use promotes youthful, healthy skin through oxygen driven cellular turnover in a breathable, second skin formula. 
Oxygenetix is the only oxygen treatment, air permeable make-up on the market. It will make your patients look great while they are recovering. It promotes healing & keeps skin looking young and beautiful.
 
Demonstrating the Foundation and Hydro-Matrix Benefits.
Yes please stop by the booth for our show promotions. 
 
Oxygenetix is the only oxygen treatment, air permeable make-up on the market. It will make your patients look great while they are recovering. It promotes healing & keeps skin looking young and beautiful.  
For more information about Oxygenetix visit www.Oxygenetix.com, email sales@Oxygenetix.com, or call 888-500-1672.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • CGI Digital Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Kentucky Rules Do Not Allow Compounding of Six Peptides Despite HHS Peptide Enforcement Policy
    • AMA Urges HHS to Withdraw Proposal Expanding Access to Certain Unapproved Peptides
    • Health Canada Warns Against Unauthorized Peptides After Bacteria Found in Seized Products
    • LRM Announces FDA Acceptance of Two INDs for Investigator-Initiated Studies of Injectable rhPDGF-BB